Last updated on June 2019

Firazyr Patient Registry (Icatibant Outcome Survey - IOS)


Brief description of study

The Icatibant Outcome Survey (IOS) is a prospective, observational disease registry designed to document the routine clinical outcomes over time in participants with angioedema treated with Firazyr (icatibant) and/or Cinryze (C1 inhibitor [human]) in countries where it is currently approved. The data collected will be used to evaluate the safety of Firazyr (icatibant) and Cinryze (C1 inhibitor [human]) in routine clinical practice and as a data source for post-marketing investigations.

Detailed Study Description

The Icatibant Outcome Survey (IOS) is a multicenter, prospective, observational study for participants treated with Firazyr (icatibant) and/or Cinryze (C1 inhibitor [human]) in countries where it is currently approved. The entry of participants in the Icatibant Outcome Survey (IOS) is at the discretion of the physician and the participant and is not a pre-requisite for prescribing Firazyr (icatibant) or Cinryze (C1 inhibitor [human]).

Clinical Study Identifier: NCT01034969

Find a site near you

Start Over

Royal Free Hospital

London, United Kingdom
  Connect »

Royal Victoria Infirmary

Newcastle Upon Tyne, United Kingdom
  Connect »

Hospital Universitario de Bellvitge

L'Hospitalet de Llobregat, Spain
  Connect »

Campbelltown Hospital

Campbelltown, Australia
  Connect »

CHU Angers

Angers Cedex 10, France
  Connect »

Derriford Hospital

Plymouth, United Kingdom
  Connect »

Royal London Hospital

London, United Kingdom
  Connect »

Hotel Dieu

Nantes, France
  Connect »

CHUS - H. Clinico U. de Santiago

Santiago de Compostela, Spain
  Connect »

Hospital Bellvitge

L'Hospitalet de Llobregat, Spain
  Connect »

Manchester Royal Infirmary

Manchester, United Kingdom
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.